{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:28:29Z","timestamp":1790051309073,"version":"4.0.1"},"reference-count":50,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,8,4]],"date-time":"2008-08-04T00:00:00Z","timestamp":1217808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Scand J Immunol"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human immunodeficiency virus (HIV) infection is a risk factor for thrombotic microangiopathy (TMA). We sought whether a severe deficiency in ADAMTS13, the enzyme specifically involved in the cleavage of von Willebrand factor, was associated with specific presenting features and outcome in HIV\u2010associated TMA. In this prospective, multicentre, case\u2013control study, 29 patients of 236 in the French Network on TMA had an HIV\u2010associated TMA. Seventeen patients with severe ADAMTS13 deficiency (ADAMTS13 &lt;5% HIV<jats:sup>+<\/jats:sup> group) were compared to 12 patients with a detectable ADAMTS13 activity (ADAMTS13 \u22655% HIV<jats:sup>+<\/jats:sup> group). HIV<jats:sup>+<\/jats:sup> patients were also compared to 62 patients with idiopathic TMA, either with (45 patients, ADAMTS13 &lt;5% idiopathic group) or without (17 patients, ADAMTS13 \u22655% idiopathic group) severe ADAMTS13 deficiency. ADAMTS13 &lt;5% HIV<jats:sup>+<\/jats:sup> patients had less AIDS\u2010related complications than ADAMTS13 \u22655% HIV<jats:sup>+<\/jats:sup> patients (23.5% versus 91.6%, respectively, <jats:italic>P\u2003<\/jats:italic>=\u20030.0005) and their median CD4<jats:sup>+<\/jats:sup> T cell count was higher (<jats:italic>P\u2003<\/jats:italic>=\u20030.05). TMA\u2010associated death rate was higher in ADAMTS13 \u22655% HIV<jats:sup>+<\/jats:sup> patients than in ADAMTS13 &lt;5% HIV<jats:sup>+<\/jats:sup> patients (50% versus 11.7%, respectively, <jats:italic>P\u2003<\/jats:italic>=\u20030.04). In ADAMTS13 &lt;5% patients, TMA\u2010associated death rate was comparable between HIV<jats:sup>+<\/jats:sup> and idiopathic patients (15.5% in idiopathic patients, <jats:italic>P<\/jats:italic>\u2010value was non\u2010significant). By contrast, TMA\u2010associated death rate in ADAMTS13 \u22655% HIV<jats:sup>+<\/jats:sup> patients was higher than in idiopathic patients (11.7% in idiopathic patients, <jats:italic>P\u2003<\/jats:italic>=\u20030.04). In conclusion, HIV\u2010associated TMA with severe ADAMTS13 deficiency have less AIDS\u2010related complications and a higher CD4<jats:sup>+<\/jats:sup> T cell count. TMA prognosis is better and comparable to this of idiopathic forms.<\/jats:p>","DOI":"10.1111\/j.1365-3083.2008.02143.x","type":"journal-article","created":{"date-parts":[[2008,8,4]],"date-time":"2008-08-04T16:14:24Z","timestamp":1217866464000},"page":"337-344","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Human Immunodeficiency Virus\u2010Associated Thrombotic Microangiopathies: Clinical Characteristics and Outcome According to ADAMTS13 Activity"],"prefix":"10.1111","volume":"68","author":[{"given":"S.","family":"Malak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. A.","family":"Millot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mariotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Veyradier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010L.","family":"Meynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.\u2010M.","family":"Korach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Malot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Boulanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Galicier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Devaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Eschw\u00e8ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gallien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Adrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Schlemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the R\u00e9seau d\u2019Etude des Microangiopathies Thrombotiques (TMA\u2010Rare Diseases Reference Center)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,8,4]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811263392202"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811263392203"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0344"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0193"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-4097"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/35097008"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1616"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02025.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","article-title":"Prognostic value of anti\u2010ADAMTS13 antibodies features (Ig isotype, titer and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with an undetectable ADAMTS13 activity","volume":"109","author":"Ferrari S","year":"2007","journal-title":"Blood"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000133622.03370.07"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-7-199804010-00004"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006153422402"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1765"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/344778"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/422363"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02565164"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199709000-00004"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000169039"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05837.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200301000-00003"},{"key":"e_1_2_6_22_2","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2006"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.5.1479"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2001.1.463"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01346.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(89)80412-7"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830400206"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2002.03349.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05325.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.78.923.520"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000188916"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-2977(97)00027-2"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0248-8663(96)81252-5"},{"key":"e_1_2_6_34_2","first-page":"117","article-title":"Human immunodeficiency virus infection and thrombotic microangiopathy","volume":"34","author":"Hymes KB","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.7.1228"},{"key":"e_1_2_6_36_2","first-page":"145","article-title":"Thrombotic microangiopathy syndrome as an AIDS\u2010defining illness: the experience of J. Stroger Hospital of Cook County","volume":"4","author":"Tamkus D","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_6_37_2","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1182\/blood.V80.8.1890.bloodjournal8081890","article-title":"Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic","volume":"80","author":"Thompson CE","year":"1992","journal-title":"Blood"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb08294.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.3109\/10623320009072210"},{"key":"e_1_2_6_40_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-0037-1613994","article-title":"Persistently elevated levels of von Willebrand factor antigen in HIV infection. Downregulation during highly active antiretroviral therapy","volume":"84","author":"Aukrust P","year":"2000","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.3.360"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.9.2774.2774"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.5.2766"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198111000-00003"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.5858\/2003-127-834-TTPAHU"},{"key":"e_1_2_6_46_2","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood.V87.8.3245.bloodjournal8783245","article-title":"Plasma from patients with idiopathic and human immunodeficiency virus\u2010associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells","volume":"87","author":"Laurence J","year":"1996","journal-title":"Blood"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328010e276"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199104000-00021"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10063"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1258\/0956462054679241"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-200008000-00010"}],"container-title":["Scandinavian Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-3083.2008.02143.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-3083.2008.02143.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T01:48:12Z","timestamp":1697248092000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-3083.2008.02143.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,4]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1111\/j.1365-3083.2008.02143.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-3083.2008.02143.x","archive":["Portico"],"relation":{},"ISSN":["0300-9475","1365-3083"],"issn-type":[{"value":"0300-9475","type":"print"},{"value":"1365-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,4]]},"assertion":[{"value":"2008-08-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}